SMS Pharmaceuticals Limited has informed the Exchange regarding change in Registered Office of the company.
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals reported strong full-year FY26 results with standalone revenue from operations of Rs 88,687 lakhs, up 13.3% from Rs 78,275 lakhs in FY25. Standalone net profit grew 28.1% to Rs 8,761 lakhs, while consolidated net profit (including associate share) surged 47.5% to Rs 10,199 lakhs. EPS improved from Rs 8.07 to Rs 9.58 on standalone basis and from Rs 8.16 to Rs 11.15 on consolidated basis. The board recommended a dividend of Rs 0.40 per share (40% payout) for FY26, subject to shareholder approval. Additionally, 50 million warrants were converted to equity shares during the year, increasing paid-up capital. Capital work-in-progress nearly quadrupled from Rs 3,467 lakhs to Rs 11,582 lakhs, indicating significant expansion activity.
The company delivered robust double-digit revenue and profit growth with strong earnings per share improvement. The dividend declaration and warrant conversion reflect shareholder-friendly actions. Significant capex expansion signals confidence in future growth, though investors should monitor working capital as inventories increased notably.